Skip to main content

Advertisement

SpringerLink
Log in

BAX and CDKN1A polymorphisms correlated with clinical outcomes of gastric cancer patients treated with postoperative chemotherapy

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

This study aims to examine the correlation between two single nucleotide polymorphisms (SNPs) of apoptosis-related genes and clinical outcomes in gastric cancer. A total of 221 patients with stage T2 and T3 gastric cancer treated with postoperative chemotherapy between 2003 and 2008 were retrospectively collected in this study to explore the association of rs4645878 located in BAX gene and rs1801270 located in CDKN1A gene with survival, recurrence, and toxicity to chemotherapy. Additionally, immunohistochemistry was used to detect the BAX expression in gastric cancer tissues. Patients carrying at least one variant genotype in BAX SNP (rs4645878) showed a significantly increased recurrence risk [hazard ratio (HR) 2.63; 95 % confidence internal (95 % CI) 1.71–4.03] and poor survival (HR 2.89; 95 % CI 1.88–4.44). Moreover, the recurrence and survival rate in patients with GA genotype was 72.7 and 24.7 %, respectively, compared with total recurrence rate of 54.8 %, P = 0.006, and compared with total survival rate of 46.6 %, P = 0.001. In addition, the GA genotype was related to lower BAX expression in gastric cancer tissues. The CDKN1A (rs1801270) mutant genotype was associated with a significantly decreased risk of hematologic toxicity [odds ratio (OR) 0.28; 95 % CI 0.12–0.63]. SNPs located in BAX and CDKN1A genes are closely associated with clinical outcomes in patients with gastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  2. Santoro R, Carboni F, Lepiane P, Ettorre GM, Santoro E. Clinicopathological features and prognosis of gastric cancer in young European adults. Br J Surg. 2007;94:737–42.

    Article  PubMed  CAS  Google Scholar 

  3. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ. MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.

    Article  PubMed  CAS  Google Scholar 

  4. Oh SY, Kwon HC, Kim SH, Lee S, Lee JH, Hwang JA, Hong SH, Graves CA, Camphausen K, Kim HJ, Lee YS. The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer. BMC Cancer. 2013;13:43. doi:10.1186/1471-2407-13-43.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. Li QF, Yao RY, Liu KW, Lv HY, Jiang T, Liang J. Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. J Korean Med Sci. 2010;25:846–52.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  6. Ellis PA, Smith IE, McCarthy K, Detre S, Salter J, Dowsett M, Lancet. Preoperative chemotherapy induces apoptosis in early breast cancer. Lancet. 1997;349:849.

    Article  PubMed  CAS  Google Scholar 

  7. Pietrantonio F, Biondani P, Ciurlia E, Fanetti G, Tessari A, Bertarelli G, Bossi I, Musella V, Melotti F, Di Bartolomeo M, Valvo F, Pellegrinelli A, Milione M, Perrone F, de Braud F. Role of BAX for outcome prediction in gastrointestinal malignancies. Med Oncol. 2013;30:610.

    Article  PubMed  Google Scholar 

  8. Fegan C, Starczynski J, Pratt G, Pepper C. The role of the bax gene polymorphism G (-248) A in chronic lymphocytic leukemia. Leukemia. 2006;20:1460–1.

    Article  PubMed  CAS  Google Scholar 

  9. Nückel H, Frey UH, Sellmann L, Bau M, Dürig J, Dührsen U, Siffert W. Bax gene G (-248) A promoter polymorphism and chronic lymphocytic leukemia: lack of association with incidence, disease stage and progression-free survival. Leukemia. 2006;20:724.

    Article  PubMed  Google Scholar 

  10. Moshynska O, Sankaran K, Saxena A. Molecular detection of the G (-248) A BAX promoter nucleotide change in B cell chronic lymphocytic leukaemia. Mol Pathol. 2003;56:205–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  11. Saxena A, Moshynska O, Sankaran K, Viswanathan S, Sheridan DP. Association of a novel single nucleotide polymorphism, G (-248) A, in the 5′-UTR of BAX gene in chronic lymphocytic leukemia with disease progression and treatment resistance. Cancer Lett. 2002;187:199–205.

    Article  PubMed  CAS  Google Scholar 

  12. Skogsberg S, Tobin G, Kröber A, Kienle D, Thunberg U, Aleskog A, Karlsson K, Laurell A, Merup M, Vilpo J, Sundström C, Roos G, Jernberg-Wiklund H, Döhner H, Nilsson K, Stilgenbauer S, Rosenquistzz R, The G. (-248) A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia. Leukemia. 2006;20:77–81.

    Article  PubMed  CAS  Google Scholar 

  13. Starczynski J, Pepper C, Pratt G, Hooper L, Thomas A, Milligan D, Bentley P, Fegan C. Common polymorphism G (-248) A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic leukemia once treatment is initiated. J Clin Oncol. 2005;23:1514–21.

    Article  PubMed  CAS  Google Scholar 

  14. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 1993;366:701–4.

    Article  PubMed  CAS  Google Scholar 

  15. Facher EA, Becich MJ, Deka A, Law JC. Association between human cancer and two polymorphisms occurring together in the p21Waf1/Cip1 cyclin-dependent kinase inhibitor gene. Cancer. 1997;79:2424–9.

    Article  PubMed  CAS  Google Scholar 

  16. Mousses S, Ozçelik H, Lee PD, Malkin D, Bull SB, Andrulis IL. Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum Mol Genet. 1995;4:1089–92.

    Article  PubMed  CAS  Google Scholar 

  17. Kibel AS, Suarez BK, Belani J, Oh J, Webster R, Brophy-Ebbers M, Guo C, Catalona WJ, Picus J, Goodfellow PJ. CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res. 2003;63:2033–6.

    PubMed  CAS  Google Scholar 

  18. Wang N, Wang S, Zhang Q, Lu Y, Wei H, Li W, Zhang S, Yin D, Ou Y. Association of p21 SNPs and risk of cervical cancer among Chinese women. BMC Cancer. 2012;12:589.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  19. Li G, Liu Z, Sturgis EM, Shi Q, Chamberlain RM, Spitz MR, Wei Q. Genetic polymorphisms of p21 are associated with risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 2005;26:1596–602.

    Article  PubMed  CAS  Google Scholar 

  20. Ozen A, Kocak Z, Sipahi T, Oz-Puyan F, Cakina S, Saynak M, Ibis C, Karagol H. The prognostic significance of p21 and Her-2 gene expression and mutation/polymorphism in patients with gastric adenocarcinoma. Med Oncol. 2013;30:357.

    Article  PubMed  Google Scholar 

  21. Wang X, Lin Y, Lan F, Yu Y, Ouyang X, Wang X, Huang Q, Wang L, Tan J, Zheng F. A GG allele of 3′-side AKT1 SNP is associated with decreased AKT1 activation and better prognosis of gastric cancer. J Cancer Res Clin Oncol. 2014;140:1399–411.

    Article  PubMed  CAS  Google Scholar 

  22. Pu X, Hildebrandt MA, Lu C, Lin J, Stewart DJ, Ye Y, Gu J, Spitz MR, Wu X. PI3 K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Lung Cancer. 2011;71:82–8.

    Article  PubMed  PubMed Central  Google Scholar 

  23. National Cancer Institute. Cancer Therapy Evaluation Program. Common toxicity criteria, version 3.0. http://ctep.cancer.gov/protocolDevelopment/Electronicapplications/ctc.htm. Accessed June 10, 2011.

  24. Huang Q, Lan F, Zheng Z, Xie F, Han J, Dong L, Xie Y, Zheng F. Akt2 suppresses GAPDH mediated-apoptosis in ovarian cancer cells via phosphorylating GAPDH at threonine237and decreasing its nuclear translocation. J Biol Chem. 2011;286:42211–20.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  25. Kawata N, Tsuchiya N, Horikawa Y, Inoue T, Tsuruta H, Maita S, Satoh S, Mitobe Y, Narita S, Habuchi T. Two survivin polymorphisms are cooperatively associated with bladder cancer susceptibility. Int J Cancer. 2011;129:1872–80.

    Article  PubMed  CAS  Google Scholar 

  26. Chen K, Hu Z, Wang LE, Sturgis EM, El-Naggar AK, Zhang W, Wei Q. Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 2007;28:2008–12.

    Article  PubMed  CAS  Google Scholar 

  27. Pietrantonio F, Biondani P, de Braud F, Pellegrinelli A, Bianchini G, Perrone F, Formisano B, Di Bartolomeo M. Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen. Transl Oncol. 2012;5:155–9.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Jeong SH, Han JH, Kim JH, Ahn MS, Hwang YH, Lee HW, Kang SY, Park JS, Choi JH, Lee KJ, Sheen SS, Lim HY. Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy. Dig Dis Sci. 2011;56:131–8.

    Article  PubMed  CAS  Google Scholar 

  29. Roninson IB. Oncogenic functions of tumour suppressor p21 (Waf1/Cip1/Sdi1): association with cell senescence and tumour promoting activities of stromal fibroblasts. Cancer Lett. 2002;179:1–14.

    Article  PubMed  CAS  Google Scholar 

  30. Danesi R, de Braud F, Fogli S, de Pas TM, Di Paolo A, Curigliano G, Del Tacca M. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Pharmacol Rev. 2003;55:57–103.

    Article  PubMed  CAS  Google Scholar 

  31. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265–79.

    Article  PubMed  CAS  Google Scholar 

  32. Wu W, Zhang W, Qiao R, Chen D, Wang H, Wang Y, Zhang S, Gao G, Gu A, Shen J, Qian J, Fan W, Jin L, Han B, Lu D. Association of XPD polymorphisms with severe toxicity in non-small cell lung cancer patients in a Chinese population. Clin Cancer Res. 2009;15:3889–95.

    Article  PubMed  CAS  Google Scholar 

  33. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33:9–23.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  34. Shiraishi K, Kohno T, Tanai C, Goto Y, Kuchiba A, Yamamoto S, Tsuta K, Nokihara H, Yamamoto N, Sekine I, Ohe Y, Tamura T, Yokota J, Kunitoh H. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non small-cell lung cancer. J Clin Oncol. 2010;28:4945–52.

    Article  PubMed  CAS  Google Scholar 

  35. Gu S, Wu Q, Zhao X, Wu W, Gao Z, Tan X, Qian J, Chen H, Xie Y, Jin L, Han B, Lu D. Association of CASP3 polymorphism with hematologic toxicity in patients with advanced non-small-cell lung carcinoma treated with platinum-based chemotherapy. Cancer Sci. 2012;103:1451–9.

    Article  PubMed  CAS  Google Scholar 

  36. Roh JW, Kim BK, Lee CH, Kim J, Chung HH, Kim JW, Park NH, Song YS, Park SY, Kang SB. P53 codon 72 and p21 codon 31 polymorphisms and susceptibility to cervical adenocarcinoma in Korean women. Oncol Res. 2010;18:453–9.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the National Natural Science Foundation of China (Grant No. 81372788), the Medical Scientific Research Key Foundation of Nanjing Command (No. 11Z032), and the Natural Science Foundation of Fujian Province Grant (No. 2014J01427) for Qiaojia Huang, and the Medical Scientific Innovation Foundation of Nanjing Command (No. MS122) for Yinghao Yu.

Conflict of interest

No potential conflicts of interest were declared.

Author information

Author notes

  1. Youdong Lin

    Present address: Department of Clinical Laboratory Medicine, Fujian Provincial Hospital, 134 Dongjie Road, Fuzhou, 350001, Fujian, China

Authors and Affiliations

  1. Department of Experimental Medicine, Fuzhou General Hospital (Dongfang Hospital), 156 North Xi-er Huan Road, Fuzhou, 350025, Fujian, China

    Xiaoting Wang, Youdong Lin, Fenghua Lan & Qiaojia Huang

  2. Department of Pathology, Fuzhou General Hospital (Dongfang Hospital), 156 North Xi-er Huan Road, Fuzhou, 350025, Fujian, China

    Yinghao Yu, Wei Liu, Feilai Xie & Xuzhou Wang

  3. Department of Oncology, Fuzhou General Hospital (Dongfang Hospital), 156 North Xi-er Huan Road, Fuzhou, 350025, Fujian, China

    Xuenong Ouyang

Authors
  1. Xiaoting Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Youdong Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fenghua Lan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yinghao Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xuenong Ouyang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wei Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Feilai Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xuzhou Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Qiaojia Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qiaojia Huang.

Additional information

Xiaoting Wang and Youdong Lin have contributed equally to this paper.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, X., Lin, Y., Lan, F. et al. BAX and CDKN1A polymorphisms correlated with clinical outcomes of gastric cancer patients treated with postoperative chemotherapy. Med Oncol 31, 249 (2014). https://doi.org/10.1007/s12032-014-0249-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0249-4

Keywords

Search

Navigation